Positive basophil activation test following anaphylaxis to pertuzumab and successful treatment with rapid desensitization

Journal of Allergy and Clinical Immunology: In Practice

Volumn 4, Issue 2, 2016, Pages 338-340

  González de Olano, David ^a   Morgado, Jose M ^b   Juárez Guerrero, Raquel ^a   Sánchez Muñoz, Laura ^b   Letellez Fernández, Javier ^a   Malón Giménez, Diego ^a   Castells, Mariana C ^c  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; CD203C ANTIGEN; CD63 ANTIGEN; CETIRIZINE; DEXAMETHASONE; DEXCHLORPHENIRAMINE; HYDROCORTISONE; LYMPHOCYTE ANTIGEN; MONTELUKAST; PERTUZUMAB; TRYPTASE; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BASOPHIL ACTIVATION TEST; BLOOD PRESSURE; BREAST METASTASIS; CASE REPORT; DESENSITIZATION; DIZZINESS; DRUG HYPERSENSITIVITY; DYSPNEA; ENZYME BLOOD LEVEL; EPIGASTRIC PAIN; FEMALE; HUMAN; IMMUNE FUNCTION TEST; OXYGEN SATURATION; PRESYNCOPE; PRICK TEST; PROTEIN EXPRESSION; PRURITUS; SKIN TEST; VOMITING; WHEEZING; ANAPHYLAXIS; BASOPHIL; BASOPHIL DEGRANULATION TEST; BREAST NEOPLASMS; IMMUNOLOGY; METABOLISM; METASTASIS; TREATMENT OUTCOME;

ADULT; ANAPHYLAXIS; ANTIBODIES, MONOCLONAL, HUMANIZED; BASOPHIL DEGRANULATION TEST; BASOPHILS; BREAST NEOPLASMS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84960353357     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2015.10.007     Document Type: Article

References (11)

1. Swain S.M., Baselga J., Kim S.B., Ro J., Semiglazov V., Campone M., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015, 372:724-734.
2. González-de-Olano D., Álvarez-Twose I., Morgado J.M., Esteban López M.I., Vega Castro A., Díaz de Durana M.D., et al. Evaluation of basophil activation in mastocytosis with hymenoptera venom anaphylaxis. Cytometry B Clin Cytom 2011, 80:167-175.
3. Castells M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol 2006, 6:271-277.
4. Breslow R.G., Caiado J., Castells M.C. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol 2009, 102:155-160.
5. Kadoyama K., Kuwahara A., Yamamori M., Brown J.B., Sakaeda T., Okuno Y. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse events reporting system, AERS. J Exp Clin Cancer Res 2011, 5:30-93.
6. Vultaggio A., Castells M. Hypersensitivity reactions to biologic agents. Immunol Allergy Clin North Am 2014, 34:615-632.
7. Maggi E., Vultaggio A., Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011, 7:55-63.
8. Demoly P., Adkinson N.F., Brockow K., Castells M., Chiriac A.M., Greenberger P.A., et al. International Consensus on drug allergy. Allergy 2014, 69:420-437.
9. Kleine-Tebbe J., Erdmann S., Knol E.F., MacGlashan D.W., Poulsen L.K., Gibbs B.F. Diagnostic tests based on human basophils: potentials, pitfalls and perspectives. Int Arch Allergy Immunol 2006, 141:79-90.
10. Valent P., Akin C., Arock M., Brockow K., Butterfield J.H., Carter M.C., et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012, 157:215-225.
11. Brennan P.J., Rodriguez Bouza T., Hsu F.I., Sloane D.E., Castells M.C. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009, 124:1259-1266.